MAD2L2 and prostate carcinoma: Interestingly, all nine selected articles reported immunohistochemical expression of REV-7 in different types of cancer, including testicular cancer [11], ovarian cancer [12], esophagus squamous cell carcinoma (SCC) [13], prostate cancer [14], colorectal cancer [15], diffuse large B-cell lymphoma [16], breast cancer [17], lung cancer [18] and skin cancer [19].